Synlab Group Selects Bruker's MALDI Biotyper System for Mass Spectrometry-based Molecular Microbial IdentificationBERLIN, Dec 03, 2009 (BUSINESS WIRE) -- At the KMIS meeting (Klinisch-Mikrobiologisch-Infektiologisches Symposium) on Dec. 3-5, 2009 in Berlin, Bruker Daltonics announces a framework agreement with Synlab (www.synlab.de) concerning molecular microbial identification based on MALDI-TOF mass spectrometry. Synlab is a European private diagnostic laboratory association, and Bruker Daltonics is the worldwide leading provider of mass spectrometry-based microorganism identification solutions. Synlab currently has more than 70 diagnostic laboratories in Germany and other European countries.
Synlab and Bruker have concluded a long-term partnership agreement in order to equip the laboratories of the Synlab association exclusively with the MALDI Biotyper system for fast and reliable molecular microbial identification. The MALDI Biotyper is currently already in routine use in Synlab's clinical microbiology centers in Trier, Weiden and Dachau in Germany. Moreover, Bruker and Synlab intend to further enlarge and refine the MALDI Biotyper reference library using well defined clinical isolates from the daily microbiology routine work of the Synlab laboratories.
The MALDI Biotyper is integrated into the Synlab laboratories' microbiology workflow, combining fast molecular identification with conventional antibiotic susceptibility testing (AST). The MALDI Biotyper reports the identification results into the existing laboratory information systems (LIS). Integration with LIS MCS (http://www.mcs-ag.com), Medat (http://www.medat.de) and Vision4health (http://www.vision4health.com) has already been established for Synlab, while integration with other LIS providers is also possible.
Dr. Ulrich Knipp, Technical Head of Microbiology at Synlab in Trier, commented: "After evaluating the MALDI Biotyper very thoroughly within the Synlab group, we are convinced that Bruker Daltonics is the most reliable partner for microbial identification based on mass spectrometry, and is providing outstanding microbiological service and support. Bruker Daltonics is fully established in the clinical microbiology market, and the MALDI Biotyper fulfils our requirements for reliability and robustness. The MALDI Biotyper represents a clear milestone substantiating our high quality molecular microbiology diagnostics."
Dr. Guido Mix, Director of Microbiology at Bruker Daltonics, added: "We are very pleased that our MALDI Biotyper fulfils the high demands of leading clinical laboratories like Synlab. Our framework contract with Synlab validates our efforts to provide comprehensive service and applications support to our customers by our dedicated microbiologists, fully developed technicians network and dedicated IT specialists for integration into various laboratory information systems (LIS)."
About the Bruker MALDI Biotyper
Bruker's dedicated MALDI Biotyper solution (http://www.bdal.com) enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. Bruker's robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in certain European countries.
ABOUT BRUKER CORPORATION (NASDAQ: BRKR)
Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information: http://www.bruker.com
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Photos/Multimedia Gallery Available: http://www.businesswire.com
SOURCE: Bruker Daltonics
Karin Hoffmann, +49-421-2205-2041
MALDI Biotyper Marketing, Bruker Daltonics